PlexusDx personalized semaglutide therapy starts at low dosestypically 0.25 mg weeklyallowing your stomach and esophagus to adjust gradually
Age, obesity, trauma, instability, bone mass, joint injury and developmental disease are common causes of OA
Tirzepatide is called a dual-agonist, because it activates two receptors
The B-PROOF trial followed 2,919 elderly patients with elevated homocysteine for two years on daily folic acid plus B12
However, a major federal initiative could change this in 2027: CMS BALANCE Model: GLP-1 Coverage Expansion On December 23, 2025, CMS announced the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth)a voluntary program that would cover GLP-1s for weight loss through participating Medicare Part D and Medicaid plans
SoWell + Medications Tirzepatide (Alone) Semaglutide (Alone) The Gap: Hydration Hydration Did you know